Q3 2025 Financial Performance - Revenues reached $4480 million, a 3% increase year-over-year[21, 93] - Adjusted EBITDA was $1400 million, up by 6% compared to the previous year[21] - Non-GAAP EPS increased by 14% to $078[21] - Free Cash Flow was $500 million[21] AUSTEDO Performance and Outlook - AUSTEDO U S revenues grew by 38% year-over-year to $601 million in Q3 2025[32] - AUSTEDO global revenues grew by 38% year-over-year to $618 million in Q3 2025[25] - The company reaffirmed its 2027 sales target for AUSTEDO at over $25 billion[29, 58] Pipeline and Strategic Updates - UZEDY revenues in Q3 2025 reached $43 million, a 24% increase year-over-year[25, 36] - The company reaffirmed its 2025 revenue outlook for UZEDY at $190 million - $200 million[35] - Global revenues for AJOVY reached $168 million in Q3 2025, a 19% increase year-over-year[25, 46] - The company is targeting olanzapine LAI FDA submission in Q4 2025[48, 63]

Core Insights - Teva Pharmaceutical Industries reported a higher-than-expected rise in third-quarter profit, driven by strong sales of its trio of branded drugs for migraines, Huntington's disease, and other conditions [1] Financial Performance - The company's third-quarter profit exceeded expectations, indicating robust financial health and effective market strategies [1] Product Performance - Strong sales from three key branded drugs contributed significantly to the profit increase, showcasing the effectiveness of Teva's product portfolio in addressing specific health conditions [1]

Financial Performance - Teva reported Q3 2025 revenues of $4.5 billion, a 3% increase year-over-year (YoY) in U.S. dollars, or 1% in local currency[2]. - Net income attributable to Teva in Q3 2025 was $433 million, compared to a net loss of $437 million in Q3 2024[20]. - Adjusted EBITDA for Q3 2025 was $1,394 million, a 5% increase from $1,327 million in Q3 2024[21]. - Operating income for Q3 2025 was $882 million, compared to an operating loss of $51 million in Q3 2024[80]. - Non-GAAP net income attributable to Teva for Q3 2025 was $910 million, compared to $798 million in Q3 2024[80]. - The company reported a consolidated income before income taxes of $646 million for the three months ended September 30, 2025, compared to a loss of $324 million in 2024[105]. Revenue Breakdown - The U.S. segment revenues increased by 12%, while Europe and International Markets segments decreased by 10% in local currency[2]. - Revenues from the United States segment in Q3 2025 were $2,483 million, a 12% increase from $2,225 million in Q3 2024, driven by higher sales of innovative and generic products[31]. - Revenues from the Europe segment in Q3 2025 were $1,235 million, a 2% decrease from $1,265 million in Q3 2024, impacted by lower revenues from generic products[45]. - Revenues from the International Markets segment were $557 million in Q3 2025, a 9% decrease from $613 million in Q3 2024, with a 10% decrease in local currency terms primarily due to the divestment of the Japan business[57]. - Revenues for the nine months ended September 30, 2025, were $6,543 million, an 8% increase from $6,060 million in 2024[100]. Product Performance - AUSTEDO revenues reached $618 million in Q3 2025, a 38% increase YoY, with an updated 2025 revenue outlook of $2.05 billion - $2.15 billion[2][5]. - AJOVY global revenues were $168 million, a 19% increase YoY, reaffirming a 2025 revenue outlook of $630 million - $640 million[2][5]. - Teva's generics portfolio showed stable growth, with global generics increasing by 2% YoY in Q3 2025[2]. - AJOVY revenues in the United States segment increased by 27% to $73 million in Q3 2025, driven by volume growth and market share gains[34]. - AUSTEDO revenues in the United States segment rose 38% to $601 million in Q3 2025, reflecting increased volumes and successful negotiations with CMS[35]. Cost and Expenses - R&D expenses in Q3 2025 were $256 million, a 7% increase YoY, primarily due to immunology projects[10]. - Selling and Marketing (S&M) expenses increased to $278 million in the three months ended September 30, 2025, compared to $259 million in 2024, a 7% rise[98]. - Legal settlements and loss contingencies adjustments for Q3 2025 included an estimated settlement provision for opioid cases of $42 million[91]. - Restructuring costs for the nine months ended September 30, 2025, amounted to $196 million, primarily related to optimization activities[91]. Cash Flow and Debt - Cash flow from operating activities in Q3 2025 was $369 million, down from $693 million in Q3 2024, primarily due to timing of sales and higher legal settlement payments[25]. - Free cash flow in Q3 2025 was $515 million, compared to $922 million in Q3 2024, reflecting lower operating cash flow and decreased proceeds from divestitures[26]. - Total debt as of September 30, 2025, was $16,790 million, down from $17,783 million at the end of 2024, mainly due to repayment of senior notes[27]. - Cash and cash equivalents decreased to $2,203 million as of September 30, 2025, down from $3,300 million at the end of 2024[83]. Future Outlook - The company projects 2025 revenues to be between $16.8 billion and $17.4 billion, with adjusted EBITDA expected to range from $4.5 billion to $5.0 billion[71]. - Teva is on track to achieve ~$700 million in net savings by 2027 through its Transformation programs[12]. - The company plans to focus on expanding its innovative and biosimilar medicines pipeline as part of its Pivot to Growth strategy[79].

Core Insights - Teva Pharmaceutical Industries Ltd. reported Q3 2025 revenues of $4.5 billion, a 3% increase year-over-year in U.S. dollars, or 1% in local currency [2] - The company is on track to achieve a non-GAAP operating profit margin target of 30% by 2027 as part of its Pivot to Growth strategy [4][5] Financial Performance - Revenues increased by 5% in U.S. dollars, or 3% in local currency, when excluding Japan BV from Q3 2024 [2] - GAAP operating income margin was 19.7%, while non-GAAP operating income margin was 28.9%, reflecting an 86 basis points increase year-over-year [2] - Net income attributable to Teva was $433 million, with diluted earnings per share of $0.37, compared to a net loss of $437 million and loss per share of $0.39 in Q3 2024 [22] Segment Performance - The United States segment saw revenues of $2.48 billion, a 12% increase compared to Q3 2024, driven by key innovative products like AUSTEDO [30][32] - The Europe segment reported revenues of $1.24 billion, a decrease of 2% compared to Q3 2024, primarily due to lower revenues from generic products [46] - The International Markets segment experienced a 9% decrease in revenues to $557 million, largely due to the divestment of the business venture in Japan [58] Key Product Performance - AUSTEDO revenues grew by 38% year-over-year to $601 million, with an increased revenue outlook for 2025 [2][7] - AJOVY revenues increased by 19% to $168 million, reaffirming the 2025 revenue outlook of $630 million to $640 million [2][7] - UZEDY revenues reached $43 million, a 24% increase, with a reaffirmed 2025 revenue outlook of $190 million to $200 million [2][7] Research and Development - R&D expenses in Q3 2025 were $256 million, a 7% increase compared to Q3 2024, driven by immunology projects [12] - The innovative pipeline achieved key milestones, including Phase 3 trial data for olanzapine LAI and FDA Fast Track designation for emrusolmin [8][12] Strategic Initiatives - Teva is focused on transforming and modernizing its business through the Teva Transformation programs, aiming for ~$700 million in net savings by 2027 [5][15] - The company has terminated exclusive discussions with a selected buyer regarding the sale of its API business and is initiating a renewed sales process [15][70]

Core Viewpoint - Teva Pharmaceutical Industries Ltd. is expected to report quarterly earnings of $0.68 per share, reflecting a year-over-year decline of 1.5%, with revenues projected at $4.35 billion, an increase of 0.4% from the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised upward by 0.4%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Estimates - The consensus estimate for 'Revenue- COPAXONE- Total' is $92.90 million, indicating a year-over-year decline of 31.2% [5]. - 'Revenue- API sales to third parties' is expected to reach $131.42 million, reflecting a year-over-year increase of 1.1% [5]. - 'Revenue- Other- Total' is projected at $165.39 million, showing a significant year-over-year increase of 62.2% [5]. Geographic Revenue Estimates - 'Geographic Revenue- Europe' is expected to be $1.30 billion, up 2.7% from the previous year [6]. - 'Geographic Revenue- International Markets' is forecasted at $592.56 million, indicating a decline of 3.3% year-over-year [6]. - 'Geographic Revenue- United States' is projected to reach $2.25 billion, reflecting a year-over-year increase of 1.1% [6]. Specific Product Revenue Estimates - 'Geographic Revenue- United States- Anda' is expected to be $371.57 million, down 2.2% year-over-year [7]. - 'Geographic Revenue- Europe- COPAXONE' is projected at $40.26 million, indicating a decline of 24.1% from the previous year [7]. - 'Geographic Revenue- International Markets- Generic products' is expected to be $460.92 million, down 3.4% year-over-year [8]. Stock Performance - Teva Pharmaceutical Industries shares have increased by 2.8% over the past month, outperforming the Zacks S&P 500 composite, which rose by 2.1% [9]. - With a Zacks Rank 2 (Buy), Teva is expected to outperform the overall market performance in the near term [10].

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment1-4Younger individuals, men, and racial and ethnic minority groups have lower rates of formal diagnoses despite the high impact the movements often have on all aspects of ...

Market Performance - The Tel Aviv Stock Exchange experienced an overall increase, with the Tel Aviv 35 Index rising by 0.45% to 3,288.20 points, the Tel Aviv 125 Index increasing by 0.74% to 3,363.38 points, and the BlueTech Global Index climbing by 1.43% to 600.56 points [1] - The All Bond corporate bond index saw a slight increase of 0.07% to 418.89 points, with total turnover reaching NIS 1.38 billion in equities and NIS 2.44 billion in bonds [1] Currency Exchange Rates - The shekel-dollar exchange rate was set 0.43% lower at NIS 3.243/$, while the shekel-euro rate decreased by 0.335% to NIS 3.752/€ [2] Notable Stock Movements - Tower Semiconductor Ltd. recorded the largest increase on the Tel Aviv 35 Index, rising by 2.67%. Other notable gainers included Teva Pharmaceutical Industries Ltd. (up 1.23%), Nice (up 1.61%), Energean plc (up 1.80%), and Bezeq Israel Telecommunications Company Ltd. (up 1.30%) [3] - Mizrahi Tefahot Bank and Israel Discount Bank also saw increases of 0.66% and 0.18%, respectively [3] Declining Stocks - Bank Leumi led the market decline, falling by 0.86% with the highest trading turnover. Other decliners included Bank Hapoalim (down 0.30%), Menora Mivtachim (down 0.89%), and Israel Corp. (down 1.03%) [4]

Core Insights - Teva Pharmaceutical Industries Ltd. will have its President and CEO, Richard Francis, present at two investor conferences in November 2025 [1][4] Company Overview - Teva is a leading innovative biopharmaceutical company with a strong generics business, committed to improving health for over 120 years [2] - The company focuses on neuroscience, immunology, complex generic medicines, biosimilars, and pharmacy brands globally [2] Upcoming Events - Richard Francis will present at the UBS Global Healthcare Conference on November 10, 2025, at 8:45 A.M. ET [4] - He will also present at the Jefferies London Healthcare Conference on November 18, 2025, at 11:00 A.M. GMT (6:00 A.M. ET) [4]

Core Points - The FDA announced a recall of over 580,000 bottles of the antihypertensive drug prazosin hydrochloride due to contamination with potential carcinogenic substances [1] - The recall was initiated by Teva Pharmaceuticals USA and Aurobindo Pharma USA earlier this month as a voluntary nationwide action [1] - The drug is used for vasodilation and lowering blood pressure, and is also commonly prescribed for nightmares and sleep issues related to PTSD [1] - The FDA classified this recall as a "Class II recall," indicating a moderate risk to health [1] Company Summary - Teva Pharmaceuticals USA and Aurobindo Pharma USA are the companies involved in the recall of prazosin hydrochloride [1] - The recall affects multiple batches of the drug, which may contain N-nitrosamine impurities formed during production or storage [1] Industry Summary - The incident highlights ongoing concerns regarding drug safety and contamination in the pharmaceutical industry [1] - Regulatory scrutiny is increasing as the FDA continues to monitor and address potential carcinogenic risks in medications [1]

Core Points - Teva Pharmaceuticals USA has recalled 580,844 bottles of Prazosin Hydrochloride due to high levels of a potentially cancer-causing chemical compound [1][5][6] - The recall includes various dosages of the medication, specifically 1 mg, 2 mg, and 5 mg, with bottle sizes ranging from 100 to 1,000 capsules [5] - The FDA classified the recall as Class II, indicating that the medication may cause temporary or medically reversible adverse health consequences, but the probability of serious adverse health consequences is remote [6] Company Summary - Teva Pharmaceuticals USA is based in Parsippany, NJ, and is involved in the production of blood pressure medications [1] - The company has not yet provided guidance on whether consumers should dispose of or return the recalled products [6][7] Industry Summary - The recall highlights ongoing concerns regarding the safety of pharmaceutical products and the regulatory oversight by the FDA [5][6] - The presence of high levels of "N-nitroso Prazosin impurity C" raises significant health concerns within the pharmaceutical industry, particularly regarding cancer risks associated with certain medications [5]